Overview

Phase Ia Study of Single Dose and Multiple Doses of XW001 in Healthy Adult Subjects

Status:
Completed
Trial end date:
2022-06-20
Target enrollment:
Participant gender:
Summary
This is the first-in-human, single-center, randomized, double-blinded, placebocontrolled, single-dose and multiple-dose escalation Phase Ia study
Phase:
Phase 1
Details
Lead Sponsor:
Hangzhou Sciwind Biosciences Co., Ltd.
Treatments:
Pharmaceutical Solutions